back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-02-04 10:51 Tx date 2024-01-30 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+125,000 vol |
125,000 | |
| Filed 2024-01-04 15:40 Tx date 2024-01-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+26,668 vol |
44,800 | |
| Filed 2024-01-04 15:39 Tx date 2024-01-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-26,668 vol |
0 | |
| Filed 2023-05-09 19:08 Tx date 2023-05-05 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights
58 - Expiration of rights
|
-18,132 vol |
0 | |
| Filed 2023-04-17 21:58 Tx date 2023-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights
56 - Grant of rights
|
+18,132 vol |
18,132 | |
| Filed 2023-04-17 21:57 Tx date 2021-09-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-03-14 13:20 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
37 - Stock split or consolidation
|
+20,001 vol |
26,668 | |
| Filed 2023-03-14 13:19 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+15,000 vol |
46,000 | |
| Filed 2023-03-14 13:19 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
+19,500 vol |
31,000 | |
| Filed 2023-03-14 13:18 Tx date 2023-03-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
+13,599 vol |
18,132 | |
| Filed 2023-01-16 17:02 Tx date 2023-01-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
+3,333 vol |
4,533 | |
| Filed 2023-01-16 17:01 Tx date 2023-01-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-3,333 vol |
6,667 | |
| Filed 2022-09-27 11:46 Tx date 2022-09-26 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Williams, Mark
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
1,000,000 | |
| Filed 2022-09-05 19:04 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+10,000 vol |
10,000 | |
| Filed 2022-09-05 19:04 Tx date 2022-08-31 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+5,000 vol |
11,500 | |
| Filed 2022-04-14 12:38 Tx date 2022-04-11 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,220
+200 vol $6.10 each |
1,200 | |
| Filed 2022-04-08 19:06 Tx date 2022-04-08 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,075
+500 vol $6.15 each |
1,000 | |
| Filed 2022-04-08 19:06 Tx date 2022-04-07 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,100
+500 vol $6.20 each |
500 | |
| Filed 2022-01-21 19:38 Tx date 2022-01-01 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+6,500 vol |
6,500 | |
| Filed 2022-01-21 19:37 Tx date 2021-09-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Rights RSUs
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-21 19:37 Tx date 2021-09-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-21 19:37 Tx date 2021-09-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-21 19:37 Tx date 2021-09-16 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2022-01-05 13:36 Tx date 2021-06-14 |
$MRVL
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Williams, Mark
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
500,000 | ||
| Filed 2021-06-25 11:09 Tx date 2021-06-14 |
$AVC
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Williams, Mark
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
450,000 | ||
| Filed 2021-06-25 11:05 Tx date 2021-06-14 |
$AVC
Marvel Biosciences Corp. (Formerly Alphanco Venture Corp.) |
Williams, Mark
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
5,000,049 | ||
| Filed 2021-02-04 12:18 Tx date 2021-02-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+235,322 vol |
457,415 | |
| Filed 2021-02-04 12:17 Tx date 2021-02-02 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-330,000 vol |
340,000 | |
| Filed 2020-12-18 19:43 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+222,093 vol |
222,093 | |
| Filed 2020-12-18 19:42 Tx date 2020-09-29 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
57 - Exercise of rights
|
-330,000 vol |
670,000 | |
| Filed 2020-08-27 13:34 Tx date 2020-08-21 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
56 - Grant of rights
|
+1,000,000 vol |
1,000,000 | |
| Filed 2020-08-27 13:33 Tx date 2018-10-22 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Rights RSUs
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-06-23 20:27 Tx date 2020-04-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+1,250,000 vol |
1,750,000 | |
| Filed 2020-06-23 20:26 Tx date 2020-02-13 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+500,000 vol |
500,000 | |
| Filed 2020-06-23 20:24 Tx date 2018-10-22 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-06-23 20:24 Tx date 2018-10-22 |
$AGN
Algernon Pharmaceuticals Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2015-12-09 Tx date 2015-12-01 |
$DMA
DiaMedica Inc. |
Williams, Mark Stephen
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$36,000
+240,000 vol $0.15 each |
1,152,500 |